The Department of Defense issued a request for information on Feb. 3 to identify Small organic Molecule Inhibitors that potently and effectively inhibit multiple drug resistance bacterial pathogens.
The SMIs must deliver results against tier 1 infectious threat pathogens, which includes bacterial threats that are either natural or engineered.
The DoD said it would accept information from all sources, including commercial companies, academia, the U.S. government and international entities.
All agencies submitting information to the RFI should supply supporting information for a unique and new process of action that does not significantly overlap current cataloged anti-bacterial pathogens for which MDR strains exist.
All submitted medications must have completed Phase 1 clinical trials for safety, tolerability and PK. Medications must also complete Single Ascending Dosing regimens with data to support use against infectious disease. A compound would have an advantage if it is delivered as a single dose or twice a day in either oral or intravenous injections.
The DoD expects that the medications submitted complete three month Toxicokinetic studies in two species and possess no issues regarding shelf life and formulation.
The RFI was issued as part of the Defense Threat Reduction Agency's Research and Development Enterprise Chemical and Biological Directorate Technologies Directorate, which seeks to enhance scientific knowledge and provide countermeasures to reduce chemical and biological threats to the military and the nation.